Phathom Pharmaceuticals Inc (PHAT NASDAQ) stock market data APIs
$14.5851
0.08(0.5%)
as of December 5, 2025
Try our APIs with
free plan!
Phathom Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Prev. Close
14.5851
Open
14.6633
High
14.804
Low
14.2192
52 wk Range
2.21-16.265
Market Cap
1 037 M
Shares Outstanding
71 138 K
Revenue
147 M
EPS
-0.15
Beta
0.433
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Phathom Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phathom Pharmaceuticals Inc data using free add-ons & libraries
Get Phathom Pharmaceuticals Inc Fundamental Data
Phathom Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 147 M
- EBITDA: -212 776 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.47
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phathom Pharmaceuticals Inc News
New
Surprising Analyst 12-Month Target For ITOT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including c...
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi...
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceuti...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
